Konstantinos Papamichael (K Papamichael)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 28

Top Topics

Patients With Inflammatory Bowel Disease

Top Venues

Alimentary pharmacology & therapeutics

Journal of clinical medicine

Therapeutic drug monitoring

Digestive diseases and sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring 46 (3) (2024)
Rachel Porth, Tina Deyhim, Samantha Zullow, Loren G Rabinowitz, Laurie B Grossberg, Xavier Roblin, Stephane Paul, Adam S Cheifetz, Konstantinos Papamichael
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab. Inflammatory bowel diseases (2024)
Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring 46 (3) (2024)
Dahham Alsoud, Dirk Jan A R Moes, Zhigang Wang, Rani Soenen, Zohra Layegh, Murray L Barclay, Tomoyuki Mizuno, Iris K Minichmayr, Ron J Keizer, Sebastian Georg Wicha, Gerrit J Wolbink, Jo Lydie Wilfried Lambert, Severine Vermeire, Annick de Vries, Konstantinos Papamichael, Núria Padullés-Zamora, Erwin Dreesen
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring (2024)
Hadi J Minhas, Konstantinos Papamichael, Adam S Cheifetz, Robert J Gianotti
A primer on common supplements and dietary measures used by patients with inflammatory bowel disease. Therapeutic advances in chronic disease 14 (2023)
Xavier Roblin, Gérard Duru, Konstantinos Papamichael, Adam S Cheifetz, Sandy Kwiatek, Anne-Emmanuelle Berger, Mathilde Barrau, Louis Waeckel, Stéphane Nancey, Stephane Paul
Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease. Journal of clinical medicine 12 (10) (2023)
Xavier Roblin, Stéphane Nancey, Konstantinos Papamichael, Gérard Duru, Mathurin Flamand, Sandy Kwiatek, Adam Cheifetz, Nicole Fabien, Mathilde Barrau, Stéphane Paul
Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease. Journal of Crohn's & colitis (2023)
Tina Deyhim, Adam S Cheifetz, Konstantinos Papamichael
Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics. Journal of clinical medicine 12 (22) (2023)
Natália Souza Freitas Queiroz, Konstantinos Papamichael, Adam S Cheifetz
Letter: is blindly stopping thiopurines without confirming adequate anti-TNF concentrations shortsighted? Alimentary pharmacology & therapeutics 55 (7) (2022)
Konstantinos Papamichael, Vipul Jairath, Guangyong Zou, Benjamin Cohen, Timothy Ritter, Bruce Sands, Corey Siegel, John Valentine, Michelle Smith, Niels Vande Casteele, Marla Dubinsky, Adam Cheifetz
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ open 12 (4) (2022)
Laurie B Grossberg, Konstantinos Papamichael, Adam S Cheifetz
Review article: emerging drug therapies in inflammatory bowel disease. Alimentary pharmacology & therapeutics 55 (7) (2022)
Gerassimos J Mantzaris, Konstantinos Papamichael
Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis. Alimentary pharmacology & therapeutics 56 (4) (2022)
Konstantinos Papamichael, Adam S Cheifetz
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. Expert opinion on drug metabolism & toxicology 17 (12) (2022)
Shana Rakowsky, Adam S Cheifetz, Konstantinos Papamichael
Editorial: is there a role for monitoring intermediate anti-TNF drug concentrations in IBD? Alimentary pharmacology & therapeutics 55 (8) (2022)
Shana Rakowsky, Konstantinos Papamichael, Adam S Cheifetz
Choosing the right biologic for complications of inflammatory bowel disease. Expert review of gastroenterology & hepatology 16 (3) (2022)
Shana Rakowsky, Adam S Cheifetz, Konstantinos Papamichael
Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. Alimentary pharmacology & therapeutics 54 (8) (2021)
Rodrigo Bremer Nones, Phillip R Fleshner, Natália Souza Freitas Queiroz, Adam S Cheifetz, Antonino Spinelli, Silvio Danese, Laurent Peyrin-Biroulet, Konstantinos Papamichael, Paulo Gustavo Kotze
Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. Journal of clinical medicine 10 (23) (2021)
Konstantinos Papamichael, Adam S Cheifetz, Peter M Irving
New role for azathioprine in case of switching anti-TNFs in IBD. Gut 69 (7) (2020)
Konstantinos Papamichael, Valerio J Thomas, Andrea Banty, William T Clarke, Katharine A Germansky, Sarah N Flier, Joseph D Feuerstein, Gil Y Melmed, Adam S Cheifetz
Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay. Journal of clinical medicine 9 (9) (2020)
Byron P Vaughn, Andres J Yarur, Elliot Graziano, James P Campbell, Abhik Bhattacharya, Jennifer Y Lee, Katherine Gheysens, Konstantinos Papamichael, Mark T Osterman, Adam S Cheifetz, Raymond K Cross
Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease. Journal of clinical medicine 9 (10) (2020)
Konstantinos Papamichael, A S Cheifetz
Letter: infliximab concentrations during induction therapy-one size does not fit all. Alimentary pharmacology & therapeutics 47 (9) (2019)
Konstantinos Papamichael, Steve Lin, Matthew Moore, Garyfallia Papaioannou, Lindsey Sattler, Adam S Cheifetz
Infliximab in inflammatory bowel disease. Therapeutic advances in chronic disease 10 (2019)
Konstantinos Papamichael, A S Cheifetz
Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease. Alimentary pharmacology & therapeutics 47 (3) (2019)
Konstantinos Papamichael, Garyfallia Papaioannou, Marcy A Cheifetz, Adam S Cheifetz
Bone of Contention: Helicobacter pylori and Osteoporosis-Is There an Association? Digestive diseases and sciences 64 (10) (2019)
Anna Juncadella, Konstantinos Papamichael, Byron P Vaughn, Adam S Cheifetz
Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. Digestive diseases and sciences 63 (11) (2018)
Konstantinos Papamichael, Ravy K Vajravelu, Mark T Osterman, Adam S Cheifetz
Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Digestive diseases and sciences 63 (3) (2018)
Konstantinos Papamichael, S Rakowsky, C Rivera, A S Cheifetz, M T Osterman
Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Alimentary pharmacology & therapeutics 47 (4) (2017)
Konstantinos Papamichael, A S Cheifetz
Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy - is less enough? Alimentary pharmacology & therapeutics 45 (9) (2017)